Target Market Determination
Released
Released
Announcement PDF
Page 1 of 5
Target Market Determination
Made by: Atomo Diagnostics Limited (ACN 142 925 684) (Company)
Product: Unlisted options to acquire fully paid ordinary shares in the Company
(Shares) under the Company’s prospectus dated 16 April 2026
(Prospectus).
The offers under the Prospectus comprise:
• an offer of up to 30,303,030 Shares at an issue price of $0.033 per
Share (SPP Shares), together with 15,151,515 new unlisted
Options ($0.045 exercise price, 2.5 year expiry) (SPP Options)
free attaching on the basis of one SPP Option for every two SPP
Shares subscribed for and issued (together, the SPP Securities)
to Eligible Shareholders under the Company's security purchase
plan (SPP) to raise up to $1,000,000 (before costs), with the ability
to accept oversubscriptions (SPP Offer); and
• an offer of up to 30,303,030 Shares at an issue price of $0.033 per
Share (Shortfall Shares), together with 15,151,515 new unlisted
Options ($0.045 exercise price, 2.5 year expiry) (Shortfall
Options) free attaching on the basis of one Shortfall Option for
every two Shortfall Shares subscribed for and issued (together, the
Shortfall Securities) to make up any shortfall (Shortfall) under the
SPP Offer (Shortfall Offer)
(together, the Offers).
Effective Date: 16 April 2026
This target market determination (TMD) has been prepared by the Company in relation to an
offer of new Options under the Prospectus pursuant to the Offers above. A copy of the
Prospectus is available on the Company’s website, www.atomodiagnostics.com.
The Offers will be made under, or accompanied by, a copy of the Prospectus. Any recipient of
this TMD should carefully read and consider the Prospectus in full and consult their professional
adviser if they have any questions regarding the contents of the Prospectus. Any recipient of this
TMD who wants to acquire Options under the Offers will need to complete the application form
that will be in, or will accompany, the Prospectus. There is no cooling off period in respect of the
issue of the Options. This TMD is not a disclosure document for the purposes of the Corporations
Act 2001 (Cth), and therefore has not been lodged, and does not require lodgement, with the
Australian Securities and Investments Commission (ASIC) nor does it contain a full summary of
the terms and conditions of the new Options.
This TMD does not take into account what you currently have, or what you want and need, for
your financial future. It is important for you to consider these matters and read the Prospectus
before you make an investment decision. The Company is not licensed to provide financial
product advice in relation to the Options.
Unless otherwise defined in this TMD, capitalised terms have the meaning given to them in the
Prospectus.
Page 2 of 5
1) Target Market
The target market for the offer of new Options pursuant to the SPP Offer under the
Prospectus is being made to those shareholders in the Company registered at the Record
Date specified in the Prospectus with a registered address in Australia and New Zealand
(Eligible Shareholders).
The Shortfall Offer is a separate offer made pursuant to the Prospectus. The Directors
reserve the right to issue the Shortfall at their absolute discretion. You may apply for
Shortfall as set out in the Prospectus.
The objectives, financial situation and needs of investors which are suitable for investment
in the Options and an explanation of why those particular financial circumstances are
suitable are provided below:
a) Investment objective
The Company expects that an investment in the Options will be suitable to investors
who wish to gain exposure to equities in a small/mid-cap health care and equipment
services company listed on the Australian Securities Exchange (ASX), and are in a
position to pay any exercise amounts in relation to the Options in due course.
b) Investment timeframe
The target market of investors will take a medium to long term outlook in relation to
their investment in the Company and are in a financial position that is sufficient for them
to invest their funds over a time period of up to 2.5 years should they wish to exercise
their Options.
c) Investor suitability metrics
While the Company does not have an established eligibility framework for investors
based on metrics such as age, expected return or volatility, it is expected that the target
market of investors will be accustomed to participating in speculative investments in the
health equipment and services sector, and will be able to withstand potential fluctuations
in the value of their investment.
The Options are not suitable for investors:
• ineligible to apply for or receive the Options;
• looking for immediate returns;
• seeking to obtain a tradeable investment, as the options will not be quoted for
trading on ASX;
• who are not seeking to have the potential to increase their investment in the
Company; and
• who do not understand and appreciate the risks of investing in options as an asset
class generally and the more specific risks of investing in an Australian listed health
care and equipment services company.
d) The Options offer no guaranteed income or capital projection
An exercise price is required to be paid to acquire Shares on exercise of new Options.
As such, the capacity to realise the underlying value of the new Options would require
that they be exercised on or before the expiry date. Investors in the target market will
need to be in a financial position to have sufficient available funds so as to facilitate an
exercise of the new Options prior to the expiry date. The new Options offer no
guaranteed income or capital protection.
Page 3 of 5
e) Risks
The Company considers that an investment in the Options will have a different risk profile
to a direct upfront investment in Shares, including due to the fact that there is no obligation
to exercise the Options prior to their expiry date.
Investors should consider the risk that there is no guarantee that the Company’s Share
price will exceed the exercise price of the Options. Investors should take this into
consideration in subscribing for Shares under the Offers and taking up their right to the
free attaching Options under the Offers.
An investment in the Options is highly speculative, such that an investment in the
Company is not appropriate for an investor who would not be able to bear a loss of some
or all of the investment. Investors should also have a sufficient level of financial literacy
and resources (either alone or in conjunction with an appropriate adviser) to understand
and appreciate the risks of investing in Options as an asset class generally and the more
specific risks of investing in an Australian listed health care and equipment services
company.
Specific risks relating to the Company and an investment in the Shares are set out in
the Prospectus and investors should review those risks carefully before deciding whether
to invest.
2) Distribution Conditions
As set out above, the new Options pursuant to the SPP Offer under the Prospectus is only
available to Eligible Shareholders.
The Shortfall Offer is a separate offer made pursuant to the Prospectus. The Directors
reserve the right to offer Options under the Shortfall at their absolute. You may apply for
Shortfall as set out in the Prospectus.
The Prospectus will include jurisdictional conditions on eligibility. The Company will also
include on its web page for the Offers a copy of this TMD and require that retail clients
confirm that they meet the eligibility criteria of the expected target market outlined in this
TMD before they apply for Options.
The Options will also be subject to the distribution condition that retail investors will be
provided with a copy of the Prospectus and access to this TMD before they apply for the
Options.
The Company considers that these distribution conditions will ensure that persons who
invest in Options fall within the target market in circumstances where personal advice is not
being provided to those persons by the Company.
Page 4 of 5
3) Review Triggers
The Options are being offered for a limited offer period set out in the Prospectus, after the
conclusion of which the Options will no longer be available for investment by way of issue.
It follows that the TMD will only apply in the period between the commencement of the offer
of the Options and the issue of the Options shortly after the close of the last of the Offers
(Offer Period), after which this TMD will be withdrawn.
To allow the Company to determine whether circumstances exist that indicate this TMD is
no longer appropriate to the Options and should be reviewed, the following review triggers
apply for the Offer Period:
a) there is a material change to the key attributes of the Options that make it no longer
consistent with the likely objectives, financial situation and needs of clients in the target
market;
b) the Company lodges with ASIC a supplementary or replacement prospectus in relation
to the Prospectus
c) any event or circumstance that would materially change a factor taken into account in
making this TMD;
d) the existence of a significant dealing of the Options that is not consistent with this TMD;
e) ASIC raises concerns with the Company regarding the adequacy of the design or
distribution of the Options or this TMD; and
f) material changes to the regulatory environment that applies to an investment in the
Options.
The Company may also amend this TMD at any time.
4) Review Period
If a review trigger occurs during the Offer Period, the Company will undertake a review of the
TMD in light of the review trigger. The Company will otherwise complete a review of the TMD
immediately prior to the issue of Options under the Offers.
5) Information reporting
The reporting requirements of all distributors is set out in the table below.
Reporting requirement Period for reporting to the
Company by the distributor
Information to be
provided
Whether the distributor • For such time as the Offer • The number of
received complaints
about the Options.
Period remains open,
within 10 business days
complaints received.
after the end of each • A summary of the
quarter. nature of each
complaint or a copy of
• Within 10 business days
after the end of the Offer
each complaint.
Period.
A significant dealing of As soon as reasonably • Details of the significant
the Options that is not practicable after the significant dealing.
consistent with this TMD dealing occurs, but in any
event no later than 10
Page 5 of 5
business days after the • Reasons why the
significant dealing occurs. distributor considers that
the significant dealing is
not consistent with this
TMD.
A summary of the steps Within 10 business days after A summary of the steps
taken by the distributor to the end of the close of the taken by the distributor to
ensure that its conduct offer of Options in accordance ensure that its conduct was
was consistent with this with the Prospectus. consistent with this TMD.
TMD.
6) Contact details
Contact details in respect of this TMD for the Company are:
Mathew Watkins
Company Secretary
Phone: +61 2 9099 4750
Email: Mathew.Watkins@vistra.com
Share your feedback
Discover